Abstract
We published rapid advice guidelines and updated guidelines for coronavirus disease 2019 (COVID-19) management on February 6, 2020, and September 4, 2020, respectively. These two guidelines vary widely in their developmental background, type of evidence, grade of recommendation and so on. We shared our experience for the development of these two guidelines to help clinical practitioners better understand and implement guidelines and to help guideline developers facilitate communication and discussion for guideline development during the pandemic.
Highlights
For Guideline 1, we were totally reliant on indirect evidence, such as that for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and influenza
Research has reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is similar to SARS-CoV, the evidence for the possible benefits of treatment in patients with SARS or MERS disease was considered indirect because the patient populations, viruses, and possibly
Indirect evidence that played an important role in guideline development during the early stage of the epidemic gradually faded when direct evidence on COVID-19 appeared
Summary
In September 2020, we registered and published an updated guideline named “Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)” Research has reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is similar to SARS-CoV (approximately 80% similar), the evidence for the possible benefits of treatment in patients with SARS or MERS disease was considered indirect because the patient populations, viruses, and possibly
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
